• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Why SciSparc Is Trading Higher By 68%, Here Are 48 Stocks Moving In Wednesday's Mid-Day Session

    9/14/22 12:28:41 PM ET
    $AA
    $ALT
    $AMTD
    $APP
    Aluminum
    Industrials
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $AA alert in real time by email

    Gainers

    • Akerna Corp. (NASDAQ:KERN) shares rose 81.2% to $0.2355 after gaining 8% on Tuesday.
    • SciSparc Ltd. (NASDAQ:SPRC) gained 68% to $1.3101 after the company announced it entered into an agreement to acquire Wellution for $20 million.
    • bioAffinity Technologies, Inc. (NASDAQ:BIAF) shares jumped 51.2% to $6.27 after the company announced publication of its research in high-throughput flow cytometry analysis of sputum in PLOS ONE.
    • My Size, Inc. (NASDAQ:MYSZ) rose 44% to $0.3194.
    • ThermoGenesis Holdings, Inc. (NASDAQ:THMO) surged 36.8% to $0.3090.
    • Avenue Therapeutics, Inc. (NASDAQ:ATXI) jumped 28.6% to $0.2992.
    • Fast Radius, Inc. (NASDAQ:FSRD) gained 23.6% to $0.6799.
    • NeuroOne Medical Technologies Corporation (NASDAQ:NMTC) rose 23% to $2.2269.
    • VistaGen Therapeutics, Inc. (NASDAQ:VTGN) jumped 19.6% to $0.2259. VistaGen Therapeutics recently announced the completion of an interim analysis of its PALISADE-2 Phase 3 clinical trial of PH94B.
    • Tenax Therapeutics, Inc. (NASDAQ:TENX) surged 18% to $0.24.
    • Evolution Petroleum Corporation (NYSE:EPM) shares gained 17.1% to $7.95 after the company posted upbeat Q4 results and reported a $25 million share repurchase program.
    • Jowell Global Ltd. (NASDAQ:JWEL) jumped 17% to $1.99.
    • RVL Pharmaceuticals plc (NASDAQ:RVLP) surged 17% to $2.96.
    • Renovacor, Inc. (NYSE:RCOR) jumped 16.6% to $2.04. BTIG initiated coverage on Renovacor with a Buy rating and announced a price target of $8.
    • AMTD IDEA Group (NYSE:AMTD) jumped 16% to $1.5091.
    • China Liberal Education Holdings Limited (NASDAQ:CLEU) gained 14.8% to $0.9184.
    • Omega Therapeutics, Inc. (NASDAQ:OMGA) rose 14% to $7.55.
    • NACCO Industries, Inc. (NYSE:NC) jumped 10.3% to $48.60.
    • Leju Holdings Limited (NYSE:LEJU) rose 9.4% to $2.09.
    • Nauticus Robotics Inc (NASDAQ:KITT) gained 8.7% to $6.50.
    • E-Home Household Service Holdings Limited (NASDAQ:EJH) rose 8.5% to $0.2088.
    • Planet Labs PBC (NYSE:PL) gained 8.3% to $6.66 on continued strength after the company recently reported better-than-expected Q2 results and raised guidance.
    • Gambling.com Group Limited (NASDAQ:GAMB) gained 8.1% to $7.99.
    • Eos Energy Enterprises, Inc. (NASDAQ:EOSE) rose 8% to $2.3550. Eos Energy Enterprises, last month, posted a Q2 loss of $1.01 per share.
    • Nikola Corporation (NASDAQ:NKLA) rose 5.8% to $5.32 following upgrade at BTIG from Neutral to Buy.


    Losers

    • Vintage Wine Estates, Inc. (NASDAQ:VWE) fell 40.5% to $3.29 after the company posted a wider Q4 loss. Telsey Advisory Group and Canaccord Genuity downgraded the stock.
    • Altimmune, Inc. (NASDAQ:ALT) fell 28.4% to $14.60 after topline results from its 12-week Phase 1b study of pemvidutide in subjects with non-alcoholic fatty liver disease (NAFLD).
    • Comera Life Sciences Holdings, Inc. (NASDAQ:CMRA) fell 25.4% to $2.8780. Comera Life Sciences shares jumped 101% on Tuesday after a late Monday Form 4 filing showed multiple insider purchases of the stock.
    • Infobird Co., Ltd (NASDAQ:IFBD) fell 23.8% to $1.8801. Infobird recently announced a 1-for-5 reverse stock split.
    • Kaspien Holdings Inc. (NASDAQ:KSPN) shares fell 23.1% to $2.20 following Q2 results. Kaspien Holdings posted a Q2 loss of $1.69 per share.
    • Caladrius Biosciences, Inc. (NASDAQ:CLBS) dipped 21.7% to $0.4001. Caladrius Biosciences announced approval of all the merger-related proposals and a name change to Lisata Therapeutics.
    • NeuroBo Pharmaceuticals, Inc. (NASDAQ:NRBO) fell 20.8% to $23.70 after jumping 79% on Tuesday.
    • Wearable Devices Ltd. (NASDAQ:WLDS) fell 18.8% to $2.3138. The company recently priced its IPO at $4 per share.
    • Aspen Group, Inc. (NASDAQ:ASPU) dropped 18.4% to $0.5593 following wider-than-expected Q1 loss.
    • InMed Pharmaceuticals Inc. (NASDAQ:INM) fell 17.3% to $9.98.
    • Yoshiharu Global Co (NASDAQ:YOSH) fell 15.8% to $2.71. The company recently priced its IPO at $4 per share.
    • MOGU Inc. (NYSE:MOGU) dipped 14.1% to $2.25. MOGU recently announced a $10 million repurchase program.
    • POINT Biopharma Global Inc. (NASDAQ:PNT) dropped 14% to $8.75 after the company priced a public offering of 13.9 million shares of common stock at $9 per share.
    • DAVIDsTEA Inc. (NASDAQ:DTEA) fell 13.2% to $1.18 after the company posted a wider Q2 loss.
    • System1, Inc. (NYSE:SST) dropped 11.4% to $8.67.
    • Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ:SHPH) dropped 11.2% to $36.57 amid post-IPO volatility after the stock began trading in late August.
    • Frequency Electronics, Inc. (NASDAQ:FEIM) fell 10.1% to $5.53. Frequency Electronics posted a Q1 loss of $0.33 per share.
    • Century Aluminum Company (NASDAQ:CENX) fell 10% to $7.45.
    • Alcoa Corporation (NYSE:AA) dropped 9.6% to $ 45.39.
    • DIRTT Environmental Solutions Ltd. (NASDAQ:DRTT) dropped 8.9% to $0.5601.
    • Sprinklr, Inc. (NYSE:CXM) dropped 8% to $11.49.
    • Transocean Ltd. (NYSE:RIG) fell 7.4% to $3.37.
    • AppLovin Corporation (NYSE:APP) dropped 6.6% to $24.91.
    Get the next $AA alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AA
    $ALT
    $AMTD
    $APP

    CompanyDatePrice TargetRatingAnalyst
    Applovin Corporation
    $APP
    3/2/2026$340.00Sell → Neutral
    Arete
    Eos Energy Enterprises Inc.
    $EOSE
    2/27/2026$20.00Buy → Neutral
    Guggenheim
    Transocean Ltd (Switzerland)
    $RIG
    2/18/2026$6.00Overweight → Equal Weight
    Barclays
    Transocean Ltd (Switzerland)
    $RIG
    2/10/2026$5.25Hold → Sell
    Pareto
    Altimmune Inc.
    $ALT
    1/28/2026$20.00Overweight
    Barclays
    Alcoa Corporation
    $AA
    1/27/2026$64.00Overweight → Equal-Weight
    Morgan Stanley
    Applovin Corporation
    $APP
    1/26/2026$700.00Hold → Buy
    Needham
    Applovin Corporation
    $APP
    1/14/2026$835.00Outperform
    Evercore ISI
    More analyst ratings

    $AA
    $ALT
    $AMTD
    $APP
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Urban David bought $100,100 worth of shares (16,250 units at $6.16), increasing direct ownership by 35% to 62,471 units (SEC Form 4)

    4 - Eos Energy Enterprises, Inc. (0001805077) (Issuer)

    3/10/26 8:52:43 AM ET
    $EOSE
    Industrial Machinery/Components
    Miscellaneous

    Chief Financial Officer Weaver Gregory L bought $17,700 worth of shares (5,000 units at $3.54), increasing direct ownership by 22% to 28,078 units (SEC Form 4)

    4 - Altimmune, Inc. (0001326190) (Issuer)

    3/9/26 7:05:04 AM ET
    $ALT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    President and CEO Durso Jerome Benedict bought $70,790 worth of shares (20,000 units at $3.54), increasing direct ownership by 160% to 32,500 units (SEC Form 4)

    4 - Altimmune, Inc. (0001326190) (Issuer)

    3/9/26 7:00:05 AM ET
    $ALT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AA
    $ALT
    $AMTD
    $APP
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    AppLovin upgraded by Arete with a new price target

    Arete upgraded AppLovin from Sell to Neutral and set a new price target of $340.00

    3/2/26 8:27:47 AM ET
    $APP
    Computer Software: Programming Data Processing
    Technology

    Eos Energy downgraded by Guggenheim with a new price target

    Guggenheim downgraded Eos Energy from Buy to Neutral and set a new price target of $20.00

    2/27/26 8:28:11 AM ET
    $EOSE
    Industrial Machinery/Components
    Miscellaneous

    Transocean downgraded by Barclays with a new price target

    Barclays downgraded Transocean from Overweight to Equal Weight and set a new price target of $6.00

    2/18/26 7:48:14 AM ET
    $RIG
    Oil & Gas Production
    Energy

    $AA
    $ALT
    $AMTD
    $APP
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Urban David bought $100,100 worth of shares (16,250 units at $6.16), increasing direct ownership by 35% to 62,471 units (SEC Form 4)

    4 - Eos Energy Enterprises, Inc. (0001805077) (Issuer)

    3/10/26 8:52:43 AM ET
    $EOSE
    Industrial Machinery/Components
    Miscellaneous

    SVP Finance and Treasurer Maxwell Thomas A sold $86,662 worth of shares (1,785 units at $48.55), decreasing direct ownership by 23% to 5,944 units (SEC Form 4)

    4 - NACCO INDUSTRIES INC (0000789933) (Issuer)

    3/9/26 5:26:09 PM ET
    $NC
    Coal Mining
    Energy

    Chief Financial Officer Weaver Gregory L bought $17,700 worth of shares (5,000 units at $3.54), increasing direct ownership by 22% to 28,078 units (SEC Form 4)

    4 - Altimmune, Inc. (0001326190) (Issuer)

    3/9/26 7:05:04 AM ET
    $ALT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AA
    $ALT
    $AMTD
    $APP
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Adjust: Gaming App Sessions Rose In 2025 As Retention Becomes A Core Growth Strategy

    Adjust's Gaming app insights report: 2026 edition finds increase in sessions, stronger paid-to-organic ratios, and growing focus on player value, retention, and measurement Leading measurement and analytics company Adjust released today its Gaming App Insights Report: 2026 Edition, highlighting continued engagement across mobile gaming and a growing industry focus on long-term player value. Global gaming app sessions saw an increase vs. last year with the paid-to-organic ratio rising 61% globally, reflecting evolving acquisition dynamics as studios balance user growth with strategies designed to deepen engagement and retention. This press release features multimedia. View the full releas

    3/10/26 10:30:00 AM ET
    $APP
    Computer Software: Programming Data Processing
    Technology

    SciSparc: Subsidiary NeuroThera Labs (75%) Signs Definitive Agreement to Acquire Majority Stake in CliniQuantum, Innovator in Quantum-based Clinical trails

    TEL AVIV, Israel, March 10, 2026 (GLOBE NEWSWIRE) -- SciSparc Ltd. (NASDAQ:SPRC) ("Company" or "SciSparc"), today announced that NeuroThera Labs Inc. (TSXV:NTLX) ("NeuroThera"), a clinical-stage pharmaceutical company focused on developing novel treatments for central nervous system disorders, in which SciSparc holds a controlling interest of approximately 75%, has entered into a definitive share purchase agreement (the "SPA"), between NeuroThera, CliniQuantum Ltd. ("CliniQ") and the Selling Shareholders (as defined below) to acquire approximately 54.01% of the issued and outstanding ordinary shares of CliniQ (the "CliniQ Shares") on a fully diluted basis immediately prior to the closing

    3/10/26 9:28:00 AM ET
    $SPRC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    AMTD Reached Deals on the Acquisition of a London Office Tower, in Conjunction with Amendment to Terms of Acquisition of the London Hornsey Town Hall Project, with Total Transaction Value at US$87.7 Million

    PARIS and NEW YORK and LONDON, March 10, 2026 /PRNewswire/ -- AMTD Group Inc. ("AMTD Group"), AMTD IDEA Group (NYSE:AMTD, SGX: HKB)), AMTD Digital Inc. (NYSE:HKD) and The Generation Essentials Group (", TGE", , NYSE:TGE, LSE: TGE), a subsidiary of AMTD Digital Inc., jointly announce that AMTD IDEA Group  entered into a term sheet (the "Term Sheet") with FEC Property Holdings (UK) Limited ("the Office Seller") and FEC Finance Limited (the "Lender") pursuant to which, among others things, (i) AMTD IDEA Group agrees to acquire from the Office Seller an office building located at 40, Furnival Street, London, EC4A 1JQ (the "Office") at a consideration of approximately US$24.0 million (the "Office

    3/10/26 9:19:00 AM ET
    $AMTD
    $HKD
    $TGE
    Finance: Consumer Services
    Finance
    Newspapers/Magazines
    Consumer Discretionary

    $AA
    $ALT
    $AMTD
    $APP
    SEC Filings

    View All

    SEC Form 6-K filed by AMTD IDEA Group

    6-K - AMTD IDEA GROUP (0001769731) (Filer)

    3/10/26 4:01:10 PM ET
    $AMTD
    Finance: Consumer Services
    Finance

    SEC Form 10-K filed by Tenax Therapeutics Inc.

    10-K - TENAX THERAPEUTICS, INC. (0000034956) (Filer)

    3/10/26 7:48:55 AM ET
    $TENX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Tenax Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - TENAX THERAPEUTICS, INC. (0000034956) (Filer)

    3/10/26 7:32:44 AM ET
    $TENX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AA
    $ALT
    $AMTD
    $APP
    Leadership Updates

    Live Leadership Updates

    View All

    Eos Energy Honors Outgoing Chair Russ Stidolph for Years of Leadership and Investment and Appoints Industry Veteran Joseph Nigro as Chair of the Board of Directors

    EDISON, N.J., Dec. 22, 2025 (GLOBE NEWSWIRE) -- Eos Energy Enterprises, Inc. (NASDAQ:EOSE) ("Eos" or the "Company") an American energy company and the leading innovator in designing, sourcing, manufacturing, and providing zinc-based battery energy storage systems (BESS) manufactured in the United States, today announced that Russ Stidolph, who has served as non-executive Chair since April 2018 and whose firm, AltEnergy, LLC, has been a lead investor in Eos for the past eleven years, has decided to step down from the Board of Directors, effective December 31, 2025, to focus his efforts, full time, on AltEnergy Acquisition Corp. The Board has appointed Joseph Nigro to succeed Stidolph as non

    12/22/25 4:36:01 PM ET
    $EOSE
    Industrial Machinery/Components
    Miscellaneous

    Vistagen Appoints Nick Tressler as Chief Financial Officer

    Vistagen (NASDAQ:VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today announced the appointment of Nick Tressler as Chief Financial Officer (CFO), effective today, December 1, 2025. "I am excited to welcome Nick to Vistagen as our CFO. His financial and strategic acumen and extensive operational experience in the biopharmaceutical industry will be instrumental as we accelerate into our next phase," said President and Chief Executive Officer of Vistagen, Shawn Singh. "I look forward to his contributions to our leadership team and the po

    12/1/25 8:30:00 AM ET
    $AZN
    $SENS
    $VTGN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical/Dental Instruments

    Altimmune Announces CEO Transition and Succession Plan

    Jerry Durso, accomplished industry leader, to succeed Vipin Garg, Ph.D. as Chief Executive Officer Transition follows seven years of strong leadership by Dr. Garg GAITHERSBURG, Md., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (NASDAQ:ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and metabolic diseases, today announced a CEO succession plan under which Vipin Garg, Ph.D. will step down as the Company's President and Chief Executive Officer effective January 1, 2026. Altimmune's Chairman of the Board, Jerry Durso, will assume the role of President and Chief Executive Officer and retain his position as Chairman. To facilitat

    12/1/25 7:30:00 AM ET
    $ALT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AA
    $ALT
    $AMTD
    $APP
    Financials

    Live finance-specific insights

    View All

    Frequency Electronics Announces Third Quarter Fiscal 2026 Financial Results Conference Call: Wednesday, March 11, 2026, at 4:30 PM ET

    MITCHEL FIELD, N.Y., March 09, 2026 (GLOBE NEWSWIRE) -- Frequency Electronics, Inc. (NASDAQ:FEIM), will hold a conference call to discuss results for the third quarter of its fiscal year 2026, ended January 31, 2026, on Wednesday, March 11, 2026, at 4:30 PM Eastern Time. This call is being webcast by Issuer Direct Corporation and can be accessed in the Investor Relations section of Frequency's web site at www.freqelec.com. Investors and analysts may also access the call by dialing 888-506-0062. International callers may dial 973-528-0011. Callers should provide participant access code: 118136 or ask for the Frequency Electronics conference call. A telephone replay of the archived call wi

    3/9/26 4:01:00 PM ET
    $FEIM
    Electrical Products
    Industrials

    Next-Generation Platforms Scale Across Energy, Wellness, and Smokeless Consumer Segments

    Issued on behalf of Doseology Sciences Inc.Equity-Insider.com VANCOUVER, BC, March 5, 2026 /CNW/ -- Consumers are voting with their wallets, and zero-sugar is winning. Zero-sugar beverages are driving 6x more dollar growth than regular varieties as buyers actively choose clean-label products with natural sweeteners and functional ingredients[1]. The global market is forecast to expand from $350 billion in 2024 toward $500 billion by 2029, fueled by health-conscious consumers who want naturally functional products without heavy processing[1]. This structural shift is creating validated demand for precision-dosed, portable formats across energy and wellness categories, positioning Doseology Sc

    3/5/26 9:00:00 AM ET
    $HLF
    $NHTC
    $NMTC
    Other Pharmaceuticals
    Health Care
    Consumer Specialties
    Consumer Discretionary

    NACCO INDUSTRIES ANNOUNCES FOURTH QUARTER AND FULL YEAR 2025 RESULTS

    CLEVELAND, March 4, 2026 /PRNewswire/ -- Q4 Highlights:Gross profit of $12.0 million increased 42% from 2024 on 5% lower revenueOperating profit of $7.6 million up 95% over 2024 and 12% over Q3 2025 Net loss of $3.8 million compared with net income of $7.6 million in 20242025 net loss includes a $6.0 million after-tax, non-cash pension settlement chargeAdjusted EBITDA of $14.3 million improved 59% over 2024 and 14% over Q3 2025FY Highlights:Net income of $17.6 million, or $2.35/share, versus $33.7 million, or $4.55/share, in 2024Adjusted EBITDA of $48.9 million compared with $59.4 million in 2024 2024 included $13.6 million of business interruption insurance recoveriesNACCO Industries® (NYSE

    3/4/26 4:47:00 PM ET
    $LAC
    $NC
    Metal Mining
    Basic Materials
    Coal Mining
    Energy

    $AA
    $ALT
    $AMTD
    $APP
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by NACCO Industries Inc.

    SC 13D/A - NACCO INDUSTRIES INC (0000789933) (Subject)

    12/17/24 3:53:36 PM ET
    $NC
    Coal Mining
    Energy

    Amendment: SEC Form SC 13D/A filed by NACCO Industries Inc.

    SC 13D/A - NACCO INDUSTRIES INC (0000789933) (Subject)

    12/17/24 3:38:59 PM ET
    $NC
    Coal Mining
    Energy

    Amendment: SEC Form SC 13D/A filed by NACCO Industries Inc.

    SC 13D/A - NACCO INDUSTRIES INC (0000789933) (Subject)

    12/17/24 3:38:47 PM ET
    $NC
    Coal Mining
    Energy